WHO Sounds Warning Over Critical Scarcity of Obesity Injections

Fewer than 10% of people that would benefit from weight-loss injections including Wegovy have access to them, states the WHO as it publishes its initial advice on the medications.

Considering over a billion individuals worldwide now living with obesity, it is urging broader and more equitable availability to this class of drugs.

According to projections, more than two billion will be obese by 2030 without intervention.

"The latest guidance affirms that excess weight is a lifelong illness that can be addressed with comprehensive and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are major barriers to universal access to the injections that can aid individuals in losing significant body mass, notes the agency.

Skinny Jab Shortage

Despite the current most optimistic case, the production of these medications could only cover approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.

The advice urges countries and companies to increase access, via strategies such as voluntary licensing.

A patent on a key compound – the primary component of a leading brand – is due to expire in a number of nations in 2026.

The Way Obesity Jabs Function

GLP-1 drugs imitate a biological compound to reduce digestion speed, suppress the appetite and increase the sense of being full so individuals consume fewer calories.

Individuals usually start to lose weight after several weeks of starting on the regular doses.

Research suggests people may put most of the weight back on within a year of stopping the medication, as their typical hunger come back.

To be above a healthy weight elevates your risk for developing health problems, such as diabetes, heart disease, stroke, and some malignancies.

Obesity concerns people in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.